MPLT
What one share of MapLight Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.
MapLight Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$7.42 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$5.65 |
| Cash and investments | $1.58 |
| Book value | $7.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$105.38 | $1.05 | −$108.11 | — | −$254.35 |
| 2025 | — | −$18.56 | $0.05 | −$15.97 | — | $10.41 |